He has told Wall Street that, if all goes as planned, operating margins will go from 11% to 15% in five years, internal sales growth will go from zero to as much as 10% and earnings per share will grow 15% a year.
Under a performance-share plan launched in 2007, executive officers get no shares if Lilly investors see zero or negative returns over a three-year period.